Altimmune announces positive interim data from alt-801 phase 1 trial in overweight and obese volunteers

Gaithersburg, md., june 16, 2021 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced results from a prespecified 6-week interim analysis of its ongoing 12-week, phase 1, placebo-controlled, single and multiple ascending dose trial of alt-801, an investigational glp-1/glucagon dual receptor agonist, in healthy overweight and obese volunteers. the study is currently being conducted in australia under a clinical trial application.
ALT Ratings Summary
ALT Quant Ranking